IASLC World Conference on Lung Cancer
The latest news from the meeting, including researcher interviews and physician perspective.
expand
SPONSORED CONTENT
September 09, 2024
2 min read
Save
Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’
Ivonescimab significantly improved PFS compared with pembrolizumab as first-line treatment of PD-L1-positive advanced non-small cell lung cancer, according to results of the HARMONi-2 trial.
SPONSORED CONTENT
September 09, 2024
3 min read
Save
Perioperative nivolumab improves outcomes in resectable NSCLC
Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.
SPONSORED CONTENT
September 09, 2024
2 min read
Save
Despite progress, barriers to lung cancer biomarker testing persist
Acceptance and utilization of lung cancer biomarker testing has increased in the past 6 years, but key barriers persist, according to survey results.